Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-833923 with cisplatin and capecitabine in first-line metastatic gastric, gastroesophageal, or esophageal adenocarcinoma
NL-OMON34104Phase 1Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BMS-833923 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Safety and toxicity and Pharmacokinetics of BMS-833923. Planned start Feb 2011; status: not yet recruiting.
02
Drugs
BMS-833923
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NL-OMON34104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34104.